Growing initiatives by government for promoting immunization is fueling the growth of cell culture media for the vaccine market
Cell
culture media for vaccine is a media that is composed of amino acids, inorganic
salts, vitamins, serum, glucose, etc. They are used to develop vaccines and
other therapies for treating a wide range of life-threatening disease
The
high prevalence of infectious disease is a key factor driving the growth of the
cell culture media for vaccine. According to the World Health Organization,
nearly 50,000 men, women, and children are dying every day from infectious
diseases. Growing initiatives and approval by the government coupled with the
rising research and development activities for developing effective vaccines is
also projected to foster the growth of the cell
culture media for vaccine market. Increasing initiatives by organization
and government for promoting immunization around the globe is again estimated
to propel the growth of the market. Moreover, a growing number of vaccine
clinical trials around the globe is further projected to propel the growth of
the market. Furthermore, the increasing availability of novel blood plasma
derivatives is further anticipated to propel the growth of the market over the
forecast period.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the increasing investment in the research and development
activities by the pharmaceutical and biotechnology industry in the region.
According to the Pharmaceutical Research and Manufacturers of America, The
entire biopharmaceutical industry invested an estimated $102 billion in
research and development (R&D) in 2018. PhRMA members invested $83 billion
in R&D in 2019, establishing the biopharmaceutical sector as the most
R&D-intensive industry in the U.S. economy.
Key Developments:
1. 1. In October 2019, Thermo Fisher
Scientific launched Cell Culture Media as First to Remain Stable When Stored at
Room Temperature. Gibco BenchStable Media is the latest offering in the Gibco
product line from Thermo Fisher Scientific and provides a flexible alternative
for biological researchers that also saves energy.
2. 2. In May 2019, Sartorius Stedim
Biotech (SSB) has introduced its new generation of Ambr® 15 Cell Culture
automated microbioreactor system. This media reduce cell line development
timelines and increase lab productivity.
3. 3. In November 2019, Thermo Fisher
Scientific has invested nearly $24 million in its biologics site at Inchinnan,
Scotland, to boost its ability to manufacture cell culture media.
4. 4. In March 2020, Lonza has launched
a new medium the TheraPEAK™ SfAAV™ Medium is specifically designed to support
the development of safe, scalable, life-saving gene therapies
Comments
Post a Comment